FDA Brief

Warning letters Drugs

FDA warning letter to

Dixon Investments Inc. dba ARI

High riskIssued Sep 17, 2025Posted Oct 7, 2025Center for Drug Evaluation and Research (CDER)

FDA cites Dixon Investments (ARI) for manufacturing-rule and unapproved/misbranded OTC aerosol drug violations.

What happened

FDA inspected the Orchard Hill, GA drug manufacturing facility from March 5 to 11, 2025 and reviewed the company’s March 27, 2025 response to the Form FDA-483, the list of inspection observations. The inspection found repeat failures in current good manufacturing practice (CGMP), the FDA rules for drug manufacturing, including missing process validation and inadequate stability testing. FDA also found that certain OTC combination first aid antiseptic/external analgesic products were unapproved new drugs and misbranded.

What FDA found

  1. The firm had not validated its manufacturing processes for OTC aerosol drugs, a repeat violation.

    21 CFR 211.100(a)
  2. The firm did not test enough batches under its written stability program to support storage conditions and expiration dates, a repeat violation.

    21 CFR 211.166(a)
  3. The quality control unit did not adequately oversee change controls, batch release, corrective actions, control-record review, and equipment cleaning and maintenance.

    21 CFR 211.22
  4. Certain combination first aid antiseptic/external analgesic products were marketed as unapproved new drugs because they did not meet the FDA standards for over-the-counter drugs and had no approved application.

    FD&C Act sections 505(a) and 301(d); 21 U.S.C. 355(a), 331(d)
  5. Labels omitted required first-aid directions and a required stop-use warning.

    FD&C Act sections 502(f)(1) and 502(f)(2); 21 U.S.C. 352(f)(1), 352(f)(2); M003.50(d), M003.50(c)(1)(ii)
  6. The products were also misbranded because they are nonprescription drugs that do not comply with section 505G and are not covered by an approved application.

    FD&C Act section 502(ee); 21 U.S.C. 352(ee)

What FDA wants

FDA tells the company to correct the violations promptly and respond in writing within 15 working days with what it has done and how it will prevent recurrence; if it cannot complete the work, it must explain the delay and give a schedule. FDA also recommends a qualified CGMP consultant and asks for detailed plans for process validation, stability testing, and quality-unit remediation.

Who should pay attention

  • distributors and retailers selling ARI OTC aerosol products
  • brands or contractors relying on this manufacturer
  • regulatory teams tracking OTC monograph labeling

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk